Jean-Pierre Bronowicki

Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.

Albert Tran, Vincent Leroy, Dominique Larrey, 2018, Gastroenterology.

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Masatoshi Kudo, Osamu Yokosuka, Gianluca Masi, 2017, The Lancet.

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

Jean-Michel Pawlotsky, Geoffrey Dusheiko, Tara L. Kieffer, 2009, The New England journal of medicine.

Longitudinal Liver Stiffness Assessment in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy

Xavier Forns, V. de Lédinghen, X. Forns, 2012, PloS one.

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.

Rachida Lebtahi, Mohamed Bouattour, Christophe Aubé, 2017, The Lancet. Oncology.

Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.

Ronald Pruitt, Stefan Zeuzem, Dominique Thabut, 2016, Journal of hepatology.

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.

Ulysses Diva, Vinod K Rustgi, P. Thuluvath, 2012, The Lancet. Infectious diseases.

Boceprevir for untreated chronic HCV genotype 1 infection.

M. Manns, J. Albrecht, K. Reddy, 2011, The New England journal of medicine.